Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 12, 2021
Share
Laboratorios Farmaceuticos Rovi, S.A. Announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was EUR 130.547 million compared to EUR 100.964 million a year ago. Operating income was EUR 29.606 million compared to EUR 15.131 million a year ago. Net income was EUR 23.838 million compared to EUR 13.919 million a year ago.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows:
- pharmaceutical products manufactured under contract (49%);
- prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%).
Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
LABORATORIOS FARMACEUTICOS ROVI, S.A. 
